Geocann and Sunderstorm expand KANHA brand internationally, becoming the first North American cannabis edibles brand to launch in Asia
December 08, 2022 12:45 ET
|
Geocann
FORT COLLINS, Colo., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Geocann and Sunderstorm are proud to announce the expansion of their partnership to key international markets that will begin with Thailand....
Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
December 01, 2022 14:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate to Participate in Benzinga All Live Access Event
November 30, 2022 15:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Oral Drug Delivery Global Market Report 2022: Rising R&D and Partnerships Between Key Players Driving Growth
November 11, 2022 08:33 ET
|
Research and Markets
Dublin, Nov. 11, 2022 (GLOBE NEWSWIRE) -- The "Oral Drug Delivery Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.People are embracing a more...
Geocann expands cannabis scientific research leadership with first human β-caryophyllene (BCP) published study demonstrating the safety and performance of novel formulation
November 09, 2022 15:15 ET
|
Geocann
FORT COLLINS, Colo., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Geocann is proud to announce that the peer-reviewed journal, Molecules, has published the results of a randomized, double-blind, cross-over...
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
November 01, 2022 09:02 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
October 24, 2022 16:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Rapid progression in Drug Delivery techniques will bolster the Oral Controlled Release Drug Delivery Technology Market to reach US$ 68.4 Bn by 2032 end. Data by Future Market Insights, Inc.
October 17, 2022 06:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The global oral controlled release drug delivery technology market is expected to reach a value of US$ 68.4 Bn in 2032, with sales growing at a healthy...
Pharmaceutical Drug Delivery Global Market Report 2022: Featuring 3M, AstraZeneca, Pfizer, Bayer, Novartis, Merck & More
September 29, 2022 04:28 ET
|
Research and Markets
Dublin, Sept. 29, 2022 (GLOBE NEWSWIRE) -- The "Pharmaceutical Drug Delivery Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global pharmaceutical drug...
Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103
September 19, 2022 06:45 ET
|
Cingulate Inc.
Data Demonstrated Ability of CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone – Setting the Stage for Future Trials Employing Cingulate’s Precision Timed Release™ (PTR™)...